000127881 001__ 127881
000127881 005__ 20240228140955.0
000127881 0247_ $$2doi$$a10.1002/ijc.28980
000127881 0247_ $$2pmid$$apmid:24839182
000127881 0247_ $$2ISSN$$a0020-7136
000127881 0247_ $$2ISSN$$a1097-0215
000127881 0247_ $$2altmetric$$aaltmetric:2359155
000127881 037__ $$aDKFZ-2017-03903
000127881 041__ $$aeng
000127881 082__ $$a610
000127881 1001_ $$0P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aZörnig, Inka$$b0$$eFirst author$$udkfz
000127881 245__ $$aPrognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
000127881 260__ $$aBognor Regis$$bWiley-Liss$$c2015
000127881 3367_ $$2DRIVER$$aarticle
000127881 3367_ $$2DataCite$$aOutput Types/Journal article
000127881 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521645161_920
000127881 3367_ $$2BibTeX$$aARTICLE
000127881 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127881 3367_ $$00$$2EndNote$$aJournal Article
000127881 520__ $$aDistribution, patterns and prognostic impact of spontaneous antibody responses against different tumor-associated antigens (TAAs) in malignant melanoma patients are unknown so far and were investigated in this study for the first time in a large cohort at different stages of the disease, identifying new prognostic biomarkers for malignant melanoma. Serum samples from 365 melanoma patients (97 Stage I melanoma patients, 87 Stage II, 92 Stage III and 89 Stage IV) and 100 age and gender matched healthy control donors were analyzed. Samples were drawn at the time of diagnosis (Stages I-III) or at time of diagnosis of distant metastasis (Stage IV). Applying a novel multiplex assay, humoral immune responses against 29 TAAs were determined and the association between response and patient survival was investigated. Antibody responses were mainly found in melanoma patients and all tested antigens elicited immune responses in all disease stages. Antibody responses against single antigens were either associated with poor prognosis and/or shorter progression-free survival (PFS) or had no influence. While in Stages I-III significant associations were observed between an antibody response and overall survival or PFS, among Stage IV patients, no significant association was found. Multivariate analyses identified specific humoral immune responses as prognostic factors independently of age, chemotherapy and immunotherapy. Antibody responses against specific TAA in Stage I-III melanoma patients correlate with poor prognosis and/or shorter PFS. These results may help to design clinical studies in order to evaluate the potential of these responses as prognostic serological biomarkers.
000127881 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000127881 588__ $$aDataset connected to CrossRef, PubMed,
000127881 650_7 $$2NLM Chemicals$$aAntigens, Neoplasm
000127881 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b1$$udkfz
000127881 7001_ $$aLorenzo Bermejo, Justo$$b2
000127881 7001_ $$0P:(DE-He78)4d7d557dd5bd769ac4d7bf2fa5da3c0f$$aZiegelmeier, Claudia$$b3$$udkfz
000127881 7001_ $$0P:(DE-He78)eed71877972a029b8b099222b2ddbe0d$$aDickes, Elke$$b4$$udkfz
000127881 7001_ $$0P:(DE-HGF)0$$aMigdoll, Alexander$$b5
000127881 7001_ $$0P:(DE-He78)b532cde04c20e4a2ce7edc5154f60cec$$aKaiser, Iris$$b6$$udkfz
000127881 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b7$$udkfz
000127881 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b8$$udkfz
000127881 7001_ $$0P:(DE-HGF)0$$aGrabe, Niels$$b9
000127881 7001_ $$aUgurel, Selma$$b10
000127881 7001_ $$aSchadendorf, Dirk$$b11
000127881 7001_ $$aFalk, Christine$$b12
000127881 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b13$$eLast author$$udkfz
000127881 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b14$$eLast author$$udkfz
000127881 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.28980$$gVol. 136, no. 1, p. 138 - 151$$n1$$p138 - 151$$tInternational journal of cancer$$v136$$x0020-7136$$y2015
000127881 909CO $$ooai:inrepo02.dkfz.de:127881$$pVDB
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4d7d557dd5bd769ac4d7bf2fa5da3c0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eed71877972a029b8b099222b2ddbe0d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b532cde04c20e4a2ce7edc5154f60cec$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000127881 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000127881 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000127881 9141_ $$y2015
000127881 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127881 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127881 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127881 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127881 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000127881 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127881 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127881 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127881 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127881 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127881 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127881 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000127881 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x0
000127881 9201_ $$0I:(DE-He78)D015-20160331$$kD015$$lTranslationale Immunologie$$x1
000127881 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lMolekulare Diagnostik Oncogener Infektionen$$x2
000127881 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x3
000127881 9201_ $$0I:(DE-He78)G183-20160331$$kG183$$lPräklinische T-Zellforschung$$x4
000127881 980__ $$ajournal
000127881 980__ $$aVDB
000127881 980__ $$aI:(DE-He78)D120-20160331
000127881 980__ $$aI:(DE-He78)D015-20160331
000127881 980__ $$aI:(DE-He78)F020-20160331
000127881 980__ $$aI:(DE-He78)G010-20160331
000127881 980__ $$aI:(DE-He78)G183-20160331
000127881 980__ $$aUNRESTRICTED